Dynavax Technologies reported $107M in Gross Profit on Sales for its fourth fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Gross Profit On Sales Change
TG Therapeutics TGTX:US USD 77K 15K
Agenus AGEN:US USD 20.69M 1.77M
Amgen AMGN:US USD 5.09B 28M
AstraZeneca AZN:LN USD 8.7B 168M
Astrazeneca AZN:US USD 8.7B 168M
Biogen BIIB:US USD 1.97B 65.9M
Biomarin Pharmaceutical BMRN:US USD 410.25M 21.19M
Bristol Myers Squibb BMY:US USD 8.89B 21M
Chimerix CMRX:US USD 814K 31.41M
Dynavax Technologies DVAX:US USD 107M 603K
Gilead Sciences GILD:US USD 5.99B 346M
Glaxosmithkline GSK:US GBP 5.2B 244M
Merk MRK:US USD 10.47B 610M
Nektar Therapeutics NKTR:US USD 15.79M 2.86M
Neurocrine Biosciences NBIX:US USD 404.3M 22.5M
Novartis NOVN:VX USD 9.16B 21M
Pfizer PFE:US USD 14.47B 2.08B
Regeneron Pharmaceuticals REGN:US USD 2.87B 255.4M
Roche Holding ROG:VX 22.04B 696M
Sarepta Therapeutics SRPT:US USD 227.63M 37.31M
Vertex Pharmaceuticals VRTX:US USD 2.02B 25.5M